Belite Bio (BLTE) Equity Average (2021 - 2026)

Belite Bio's Equity Average history runs 5 years deep, the most recent figure standing at $783.1 million for Q1 2026.

• In Q1 2026, Equity Average rose 415.41% year-over-year to $783.1 million; the TTM figure through Mar 2026 stood at $783.1 million (up 415.41% YoY), while the FY2025 annual figure was $458.2 million, up 287.85% from the prior year.
• Equity Average was $783.1 million for Q1 2026 at Belite Bio, up from $522.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $783.1 million in Q1 2026 to a low of $38.3 million in Q1 2023.
• Historically, Equity Average has averaged $190.3 million across 4 years, with a median of $113.4 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Equity Average soared 45.91% in 2025, then surged 415.41% in 2026.
• A 4-year view of Equity Average shows it stood at $71.6 million in 2023, then jumped by 80.15% to $129.0 million in 2024, then soared by 304.84% to $522.3 million in 2025, then soared by 49.94% to $783.1 million in 2026.
• The last three Equity Average figures came in at $783.1 million (Q1 2026), $522.3 million (Q4 2025), and $212.0 million (Q3 2025), per Business Quant data.